Advertisement
EDIT vs PRME
Which Stock Would AI Choose? Editas Medicine (EDIT) vs. Prime Medicine (PRME) Stock Comparison
Key Takeaways
- Both EDIT and PRME are clinical-stage gene-editing biotechnology companies, but they use different editing technologies and target different disease pipelines.
- Editas Medicine is advancing its lead in vivo candidate EDIT-401 toward first-in-human trials for high cholesterol, while Prime Medicine is progressing multiple programs across Wilson disease, AATD, and CGD.
- EDIT reported a narrower-than-expected quarterly loss and a cash runway into the second half of 2028, whereas PRME's cash is projected to fund operations into 2027.
- Recent regulatory milestones — including Australian clearance for EDIT-401 and FDA clearance plus first patient dosing for PRME's programs — have driven sentiment in both names.
- Both stocks carry elevated risk as pre-revenue companies whose valuations hinge on clinical data, funding, and regulatory outcomes.
- For deeper coverage, explore EDIT Major News and EDIT Today's Price Move, as well as PRME Major News and PRME Today's Price Move.
- To see how automated systems are positioning across the market, explore Trending AI Robots.
Introduction
Editas Medicine (EDIT) and Prime Medicine (PRME) are two of the most closely watched names in the gene-editing space, yet they pursue distinct scientific approaches and market opportunities. Both companies are developing potentially curative, one-time therapies for genetic diseases, which makes them natural comparators for investors evaluating next-generation biotechnology. Because neither company yet generates meaningful product revenue, their stock comparison hinges on pipeline progress, cash positions, and regulatory momentum rather than conventional earnings. This relative performance analysis is most relevant for growth-oriented and biotech-focused investors who are comfortable with the elevated volatility and binary, data-driven risk profile common to clinical-stage gene-editing companies.
EDIT Overview and Recent Performance
Editas Medicine is a pioneer in CRISPR-based gene editing, using CRISPR/Cas9 systems to develop in vivo therapies that modify genes directly inside the body. The company has refocused its pipeline around EDIT-401, an experimental one-time therapy targeting the LDLR gene for heterozygous familial hypercholesterolemia (HeFH), an inherited condition causing dangerously high LDL ("bad") cholesterol. Recent weeks brought a key milestone: clearance to initiate a Phase 1/2 clinical trial of EDIT-401 in Australia. In its latest quarterly report, EDIT posted collaboration and R&D revenue of roughly $11.9 million and a narrower-than-expected net loss, while reporting approximately $211.6 million in cash expected to fund operations into the second half of 2028. The stock has shown notable strength, with shares up substantially year to date, though price swings remain pronounced around preclinical data and analyst rating changes.
PRME Overview and Recent Performance
Prime Medicine develops therapies using its proprietary Prime Editing platform, which is designed to make precise DNA edits without introducing double-stranded breaks — a distinction from the cut-and-repair approach used in CRISPR/Cas9. The company's pipeline spans PM577a for Wilson disease, PM647 for Alpha-1 Antitrypsin Deficiency (AATD), and PM359 for chronic granulomatous disease (CGD). Recent market activity has been supported by multiple regulatory advances: FDA clearance of an Investigational New Drug (IND) application for PM647, first patient dosing in the global Phase 1/2 study of PM577a, and a favorable arbitration ruling affirming its rights to PM647. In its most recent quarter, PRME reported a net loss of approximately $42.1 million and roughly $108.8 million in cash, with a runway into 2027.
Trending AI Robots
Tickeron operates a large ecosystem of AI trading bots that monitor and trade thousands of tickers across the market. Because not every automated strategy performs equally in shifting conditions, Tickeron curates only the strongest, most market-appropriate bots into a dedicated Trending AI Robots section. These bots vary widely in trading style, strategy, timeframe, performance statistics, and the specific sets of tickers they trade, so investors can evaluate options aligned with different risk tolerances and horizons. For those interested in how machine-driven systems are navigating current market conditions across names like EDIT and PRME, reviewing the curated Trending AI Robots page offers a practical starting point.
Head-to-Head Comparison
Although both companies operate in gene editing, their business models and growth drivers diverge. Editas Medicine is concentrated around a single lead program, EDIT-401, giving it a focused but comparatively narrower catalyst set; its thesis leans heavily on in vivo liver editing and a cholesterol-reduction mechanism that its management argues can exceed the efficacy ceiling of existing PCSK9-targeting therapies. Prime Medicine, by contrast, runs a broader, more diversified pipeline backed by a distinct editing technology, with nearer-term validation from its CGD program and a multi-indication roadmap.
On financial positioning, EDIT's cash runway into the second half of 2028 is longer than PRME's runway into 2027, which may reduce near-term dilution risk for Editas. However, PRME's wider pipeline creates multiple potential inflection points. In terms of momentum, both stocks have benefited from recent regulatory and clinical headlines, but their relative performance remains volatile, and each carries substantial binary risk tied to early-stage data. Market sentiment in both names is heavily influenced by broader biotech fund flows and sector-wide risk appetite.
Tickeron AI Verdict
Based on observable factors such as trend consistency, catalyst density, and relative positioning, Tickeron's AI would likely assign a modest edge to one of these names rather than a definitive preference. Prime Medicine currently presents a broader set of near-term catalysts — including first-patient dosing, FDA clearances, and a potential BLA (Biologics License Application) pathway for PM359 — which may support more sustained momentum and data-driven re-rating opportunities. Editas Medicine, meanwhile, offers a longer cash runway and a tightly focused, potentially differentiated program, though its value remains concentrated in a single candidate. In probabilistic terms, the AI's assessment would tend to favor the stock demonstrating more consistent trend stability and multiple independent catalysts, while acknowledging that both remain high-risk, data-dependent positions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and PRME is a Hold.
EDIT in downward trend: price may drop because broke its higher Bollinger Band on October 28, 2026
EDIT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 42 similar instances where the stock broke above the upper band. In 41 of the 42 cases the stock fell afterwards. This puts the odds of success at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 48 cases where EDIT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
EDIT moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for EDIT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on EDIT as a result. In 67 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for EDIT just turned positive on October 27, 2026. Looking at past instances where EDIT's MACD turned positive, the stock continued to rise in 38 of 48 cases over the following month. The odds of a continued upward trend are 79%.
Following a +22.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 180 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.793) is normal, around the industry mean (3.051). P/E Ratio (-3.939) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
PRME's RSI Oscillator peaks and leaves overbought zone
The 10-day RSI Oscillator for PRME moved out of overbought territory on October 30, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 instances where the indicator moved out of the overbought zone. In 17 of the 17 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 36 of 40 cases where PRME's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
PRME broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on PRME as a result. In 55 of 64 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for PRME just turned positive on October 06, 2026. Looking at past instances where PRME's MACD turned positive, the stock continued to rise in 29 of 35 cases over the following month. The odds of a continued upward trend are 83%.
PRME moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PRME crossed bullishly above the 50-day moving average on October 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +48.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRME advanced for three days, in 159 of 194 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 98 of 114 cases where PRME Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.413) is normal, around the industry mean (3.051). P/E Ratio (-4.333) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (128.205) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. PRME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
EDIT | PRME | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 85 | 83 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 56 Fair valued | 27 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 95 | |
PRICE GROWTH RATING 1..100 | 69 | 35 | |
P/E GROWTH RATING 1..100 | 35 | 89 | |
SEASONALITY SCORE 1..100 | 90 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PRME's Valuation (27) in the null industry is in the same range as EDIT (56) in the Biotechnology industry. This means that PRME’s stock grew similarly to EDIT’s over the last 12 months.
PRME's Profit vs Risk Rating (100) in the null industry is in the same range as EDIT (100) in the Biotechnology industry. This means that PRME’s stock grew similarly to EDIT’s over the last 12 months.
PRME's SMR Rating (95) in the null industry is in the same range as EDIT (99) in the Biotechnology industry. This means that PRME’s stock grew similarly to EDIT’s over the last 12 months.
PRME's Price Growth Rating (35) in the null industry is somewhat better than the same rating for EDIT (69) in the Biotechnology industry. This means that PRME’s stock grew somewhat faster than EDIT’s over the last 12 months.
EDIT's P/E Growth Rating (35) in the Biotechnology industry is somewhat better than the same rating for PRME (89) in the null industry. This means that EDIT’s stock grew somewhat faster than PRME’s over the last 12 months.
| EDIT | PRME | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 80% | 2 days ago 86% |
| MACD ODDS (%) | 2 days ago 79% | 2 days ago 83% |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 85% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 79% |
| Advances ODDS (%) | 8 days ago 80% | 8 days ago 82% |
| Declines ODDS (%) | 3 days ago 90% | 3 days ago 88% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EDIT’s FA Score shows that 0 FA rating(s) are green while PRME’s FA Score has 1 green FA rating(s).
- EDIT’s FA Score: 0 green, 5 red.
- PRME’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EDIT’s TA Score shows that 3 TA indicator(s) are bullish while PRME’s TA Score has 6 bullish TA indicator(s).
- EDIT’s TA Score: 3 bullish, 5 bearish.
- PRME’s TA Score: 6 bullish, 4 bearish.
Price Growth
EDIT (@Biotechnology) experienced а 0.00% price change this week, while PRME (@Biotechnology) price change was +4.60% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.87%. For the same industry, the average monthly price growth was -11.47%, and the average quarterly price growth was -16.77%.
Reported Earning Dates
EDIT is expected to report earnings on Nov 09, 2026.
PRME is expected to report earnings on Nov 06, 2026.
Industries' Descriptions
@Biotechnology (-3.87% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
PRME and
Correlation & Price change
A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To PRME | 1D Price Change % | ||
|---|---|---|---|---|
| PRME | 100% | +2.48% | ||
| CRSP - PRME | 66% Loosely correlated | N/A | ||
| BEAM - PRME | 64% Loosely correlated | +1.78% | ||
| RXRX - PRME | 62% Loosely correlated | -3.92% | ||
| EDIT - PRME | 62% Loosely correlated | +1.17% | ||
| RCKT - PRME | 55% Loosely correlated | +1.62% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| FLUX.X | 0.057600 | 0.001978 | +3.56% |
| Flux cryptocurrency | |||
| ZRX.X | 0.095990 | 0.001796 | +1.91% |
| 0x Protocol cryptocurrency | |||
| SHIB.X | 0.000005 | N/A | +1.38% |
| Shiba Inu cryptocurrency | |||
| GAL.X | 0.803060 | -0.004042 | -0.50% |
| Galatasaray Fan Token cryptocurrency | |||
| FRONT.X | 0.016400 | -0.001078 | -6.17% |
| Frontier cryptocurrency | |||